http://cellceutix.com/cellceutix-hits-major-milest

New Post Public Reply Private Reply Replies (1) Message Board

Nov 7, 2012 at 4:43 PM

http://cellceutix.com/cellceutix-hits-major-m...hospitals/

Cellceutix Hits Major Milestone in Company History; Dosing Underway for New Cancer Drug at Leading Hospitals

Kevetrin is First-in-Class of Novel Chemistry to Reach Clinical Stage

BEVERLY, MA – November 8, 2012– Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that dosing of patients is now being conducted in clinical trials with Kevetrin(TM), the Company’s novel anti-cancer drug candidate, at Harvard University’s Dana Farber Cancer Center and Beth Israel Deaconess Medical Center.

This major milestone transitions Cellceutix into a clinical stage biotech company with a novel drug in some of the leading cancer hospitals in the world. Kevetrin has reached its initial clinical stage goal of Phase 1 human trials for solid tumors and the protocol is now being written for clinical trials in blood cancers at university-sponsored studies in Europe.

“These advancements for a small biotech company could not have been possible without the dedication and passion our whole team demonstrated working on Kevetrin,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “Kevetrin has shown in laboratory studies to activate p53, ‘the Guardian Angel Gene,’ to reduce tumor volume and slow tumor progression in cancers which other drugs were ineffective in doing so. A completely new class in chemistry, we believe that our novel drug is something that the cancer industry has been in search of for decades. We have extremely high expectations for Kevetrin.”

About Kevetrin™

As a completely new class of chemistry in medicine, Kevetrin™ has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin’s unique ability to affect both wild and mutant types of p53 (often referred to as the “Guardian Angel Gene” or the “Guardian Angel of the Human Genome”) and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.

In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein’s protective function, which Kevetrin appears to be doing the majority of the time.

The clinical trial titled, “A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors,” is available at: http://clinicaltrials.gov/ct2/show/NCT0166400...amp;rank=1

About Cellceutix

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today’s cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix’s success are more fully disclosed in Cellceutix’s most recent public filings with the U.S. Securities and Exchange Commission.

Site Navigation
Home
Our Team
Product Pipeline Kevetrin™ Compound
Prurisol Compound
Autism Compound

Investors Press Releases
In the News
Events and Presentations
Stock Information
Financial Information
Contact Us

Cellceutix

100 Cumming Center, Suite 151-B Beverly, MA 01915 Phone : 978-236-8717 Email: info@cellceutix.com

© 2012 Cellceutix Corporation All rights reserved.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Denison Mines' Q3 2026: Construction and Results Unveiled

Progress at Phoenix ISR Uranium Mine The numbers out from Denison Mines Corp. have got me feeling a mix of cautious optimism and worn-out fatigue, like spotting a $20 bill on a busy street. Their latest earnings release for Q3 2026 carries quite the story — beyond just spreadsheets. The highlight, of course, is the Phoenix ISR uranium mine where they're making tracks...

WuXi Biologics Racks Up Top Honors for ESG Excellence

WuXi Strikes Gold with ESG Distinction Take a look under the hood, and you’ll find that WuXi Biologics (2269.HK) isn’t just playing the long game—they’re redefining it. They’ve clinched not one, but two prestigious honors from the Hong Kong ESG Reporting Awards (HERA). And with sustainability in the hot seat worldwide, these wins are no small potatoes. They...

Blackbird Health Expands Northern VA Mental Health Care

Another Piece to the Puzzle in Pediatric Care Consider this a lifeline tossed to the scrambling families of Northern Virginia. Blackbird Health's newest clinic in Sterling is throwing open its doors to more kids and parents. Right now, the stakes couldn't be higher for families tangled in mental health mysteries, looking for every shred of support they can find. Answering...

Sentra Snags $150M to Shield Data in AI Era

By Kelly Martin Updated Nov 4, 2026 Category News Views 237

Agents in the Data Game Who would've thought data would need protection from its own minders? That's what Sentra's addressing with their smart pivot to 'agentic' data security. AI agents are out there gobbling data faster than a trader overdosing on coffee during a bull run. As AI's pace accelerates, Sentra spotted an opportunity to safeguard data from unauthorized eyes....

Lakefront Living: Steuben County's Twin Tales

Here’s how it is: choosing a lakefront home in Steuben County, Indiana, ain't just about picking a place with a killer view. It’s like buying a lifestyle package and you’d better know what you’re getting. An article by Tony Isa, the go-to real estate guru in these parts, puts the spotlight on Lake James and Clear Lake—but what matters is how each might wrangle...

Enova Announces $600M Senior Notes Offering

By Evelyn Baker Updated Nov 4, 2026 Category News Views 104

$600 Million Senior Notes: Enova's Financial Move Enova International is pulling the trigger on a financial maneuver that’s got the market buzzing today. They’re planning to drop a hefty $600 million in senior notes onto the table, all set to mature in 2031. It's a big slice of the pie, but the game plan stitched to it? Well, that's where it gets interesting. A...

Ecobat Workers Secure Landmark Three-Year Contract

A Breakthrough for Ecobat Workers Man, when it comes to contracts, this recent deal at Ecobat is as game-changing as they get. A vote just ripped through like a hurricane, with 220 workers under Teamsters Local 986 eagerly ratifying a new three-year agreement that signals more than just a better payday. We're talking the largest wage boost these folks have clapped eyes on...

Basildon Build-to-Rent Marks Progress for Starlight

Basildon's New Housing Beacon Nears Completion No two construction milestones are the same, and Starlight Investments sure knows how to make theirs count. Reaching the skies with their project 'The Mercantile' in Basildon, the company has announced topping out—a significant phase in their build-to-rent development saga. With the structural peak reached, we're talking...

AI Governance Market to Hit $12.5B by 2030

AI Governance: The Enforcer's Playground Well, with every Tom, Dick, and Harry out there tinkering with artificial intelligence, it's no shocker we've come to this. Peeled back, the AI governance platforms market's pegged to hit a whopping $12.5 billion by 2030. The AIMG's report spells this out with the kind of clarity even an intern could appreciate. But here's the rub:...

RSPO RT2026 Tackles Indonesian Fires and Export Shifts

Indonesia's Burning Questions There's been a lot of smoke—literally and figuratively—hanging over the palm oil industry in Indonesia this year. At the RSPO's Annual Roundtable on Sustainable Palm Oil (RT2026), attendees didn't shy away from addressing the harsh realities. In a year marked by rampant fires, thanks to the blistering El Niño, the RSPO showcased data...